Sun Pharma Advanced Research Company reported a landmark turnaround in FY26, posting a standalone net profit of ₹1,55,213 lakhs against a loss of ₹34,522 lakhs in FY25, primarily driven by ₹1,84,002 lakhs recognised from the sale of a Priority Review Voucher for Sezaby® for USD 195 million. Consolidated equity improved to ₹1,33,882 lakhs from a negative ₹21,695 lakhs, with total consolidated assets rising to ₹2,17,086 lakhs.
SPARC Swings to Massive Profit in FY26 on Back of USD 195 Million Priority Review Voucher Sale
